11,11-Dimethyl-5,11-dihydroindeno[1,2-b]carbazole

We are 11,11-Dimethyl-5,11-dihydroindeno[1,2-b]carbazole CAS:1260228-95-2 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:11,11-Dimethyl-5,11-dihydroindeno[1,2-b]carbazole
CAS.NO:1260228-95-2
Synonyms:11,11-dimethyl-5,11-dihydroindeno[1,2-b]carbazole
5,11-dihydro-11,11-dimethylindene[1,2-b]carbazole
Molecular Formula:C21H17N
Molecular Weight:283.36600
 
Specification:
Appearance:White to off-white crystalline powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:OLED intermediates

11,11-Dimethyl-5,11-dihydroindeno[1,2-b]carbazole


Related News: With nearly 194 billion US dollars of original research medicines facing the expiration of patents in the past five years, more and more domestic companies are focusing on the corresponding characteristic APIs, and have started research and development and production preparations in advance. The scale of production and export of APIs will continue to expand and grow.4-Aminopyrazolo[3,4-d]pyrimidine CAS:2380-63-4 Exceeding impurities in the drug substance may cause the product and its preparation to be recalled. The company receives an FDA warning letter or a CEP certificate suspension, which in turn will cause customer compensation, product recall costs, and asset impairment losses to affect the company’s performance.2-Ethyl-4-methyl thiazole Exceeding impurities in the drug substance may cause the product and its preparation to be recalled. The company receives an FDA warning letter or a CEP certificate suspension, which in turn will cause customer compensation, product recall costs, and asset impairment losses to affect the company’s performance.2-[N-(2-hydroxyethyl)-4-(2-methoxyethylamino)-3-nitroanilino]ethanol CAS:23920-15-2 Only when the drug substance is processed into a pharmaceutical preparation can it become a drug for clinical application.This means that the drug attributes of the drug substance will be lost in the future, and the monopoly power of some drug substances will also be lost. The preparation company will become the main person in charge of the drug. The drug preparation company will be responsible for the quality of the original excipients. It will be more cautious, some raw and auxiliary materials companies whose quality cannot be guaranteed will be gradually eliminated, and the industry concentration will be further improved.

Related Products
Product Name
N-Boc-L-valine methyl ester View Details
2-Amino-5-bromo-3-methylpyridine View Details
2-N-(4-chlorophenyl)benzene-1,2-diamine View Details
2-benzyl-2-(dimethylamino)-4′-morpholino-butyroph manufacturer (S)-3-Amino-3-phenylpropionic acid manufacturer Growth hormone releasing peptide manufacturer 2′-Fluoroacetophenone manufacturer 3-Bromo-5-chloro-2-methoxypyridine manufacturer